Wai Conrad 的 Form 4/A 修正申報
修正Clover Health Investments, Corp.（CLOV），2025/7/10 申報
- 申報編號
- 0001801170-25-000170
- 申報時間
- 2025/7/10
- 交易日
- 2024/9/13-2025/7/8
- 申報延遲
- 300 天
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2024/9/17
這份申報列了 2 筆非衍生性交易。沿用原件裡沒有重述的 2 筆交易。公開市場賣出合計 $4.96 萬。交易後 300 天申報。
這份修正申報重述了 0001801170-24-000192（2024/9/17 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Wai ConradCIK 0001971702 | 高階主管（CEO, Counterpart Health） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/9/13 | Class A Common Stock | A公司授予取得 | +379,866 | $0.00 | $0 | 1,699,767 | 直接 | |
| 2025/7/8 | Class A Common Stock | S賣出處分 | −15,203 | $3.26 | −$49,561.78 | 1,613,498 | 間接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001801170-24-000192（2024/9/17 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/9/13 | Class A Common Stock | F扣股繳稅處分 | −93,180 | $2.99 | −$278,608.2 | 2,950,349 | 直接 | |
| 2024/9/14 | Class A Common Stock | F扣股繳稅處分 | −98,217 | $2.99 | −$293,668.83 | 2,852,132 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed to reflect the full number of RSUs that were achieved.
- F2
Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through July 10, 2025.
- F3
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.27, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4
Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.